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Objectives: To test the efficacy of EDP-420, a new ketolide, in experimental pneumococcal meningitis
and to determine its penetration into the CSF.
Methods: The experimental rabbit model was used in this study and EDP-420 was tested against a
penicillin-resistant and a penicillin- and quinolone-resistant mutant. EDP-420 was also tested against
both strains in time-killing assays over 8 h in vitro.
Results: In experimental meningitis, EDP-420 produced a bactericidal activity comparable to the stan-
dard regimen based on a combination of vancomycin with ceftriaxone against a penicillin-resistant
Streptococcus pneumoniae and a penicillin- and quinolone-resistant S. pneumoniae isolate. The pen-
etration of EDP-420 into inflamed meninges was 38% after an iv injection of 10 mg/kg. The bactericidal
activity of EDP-420 was also confirmed in in vitro time-killing assays.
Conclusions: EDP-420 is an efficacious alternative treatment in pneumococcal meningitis, especially
when resistant strains are suspected.
Keywords: pneumococcal meningitis, ketolide, resistance
Introduction
The continuous spread of penicillin-resistant pneumococci has
significantly complicated the treatment of pneumococcal infec-
tions.1 The epidemiological situation is clearly deteriorating
worldwide. Based on a recent surveillance study (PROTEKT)
including 69 centres in 25 countries, the overall penicillin resist-
ance ranged from 25% to 53%. The highest resistance rates were
reported in Asia (53.4%), followed by France (46.2%) and Spain
(42.1%), whereas in the Netherlands all strains were susceptible
to penicillin.2 In addition, resistance to erythromycin A was
even higher (from 31.1% to 79.6%) with the highest rates
observed in Asia. In that study, all strains were susceptible to
telithromycin. These data emphasize the need for alternative
regimens for pneumococcal diseases. In a more recent study in
the USA, telithromycin retained activity against erythromycin-
resistant [mainly mef(A)-positive] strains.3
Based on actual guidelines, the empirical treatment of
pneumococcal meningitis consists of a combination of a
third-generation cephalosporin with vancomycin, especially
when resistant strains are suspected.4 However, the constantly
increasing number of pneumococcal isolates resistant to
cephalosporins (cefuroxime, cefixime and cefpodoxime with
resistance rates ranging from 62% to 68% in Asia) might
jeopardize the use of cephalosporins in the empirical treat-
ment of pneumococcal meningitis.2 Furthermore, the unreli-
able penetration of vancomycin in case of adjunctive steroid
therapy might compromise the efficacy of the empirical
treatment.5
Little is known about the role of macrolides or ketolides in
the treatment of meningitis. To our knowledge, no data are
available about the role of telithromycin in pneumococcal
meningitis.
The aim of this study was to test EDP-420, a new class of
bicyclolide (a bridged bicyclic macrolide) with excellent activity
against pneumococci, in an experimental meningitis model
using a penicillin-resistant and a penicillin- and quinolone-resist-
ant Streptococcus pneumoniae isolate.
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Materials and methods
Pneumococcal strain
The pneumococcal strain WB4 (MIC of penicillin is 4 mg/L, ser-
ogroup 6) was isolated from the blood of a patient at the Inselspital
in Bern and was provided by the Institute for Infectious Diseases at
the University of Bern. This strain was grown in Mueller–Hinton
broth until an approximate density of 108 cfu/mL and was then
diluted to 106 cfu/mL for in vivo experiments. MICs were deter-
mined in liquid culture and growth was controlled after 6, 12 and
24 h because of the spontaneous autolysis of pneumococci. The
MICs of ceftriaxone, vancomycin and EDP-420 were 0.5, 0.12 and
0.06 mg/L, respectively. The quinolone-resistant strain was obtained
by sequential exposure of the strain WB4 to trovafloxacin. The
MICs after this exposure were 4 mg/L for penicillin, 0.5 mg/L for
ceftriaxone, 0.12–0.25 mg/L for vancomycin, 4 mg/L for trovafloxa-
cin, 32 mg/L for ciprofloxacin and 0.06 mg/L for EDP-420.
Experimental meningitis model
The experimental rabbit meningitis model described by Dacey and
Sande6 was used in this project. The experimental protocols were
approved by the federal veterinary office of the county of Bern.
Pathogen-free New Zealand rabbits weighing 2.5–3 kg were pro-
vided by the Zentraltiersta¨lle der Medizinischen Fakulta¨t der
Universita¨t Bern, where all the experiments were performed.
One day before an experiment, rabbits were anaesthetized by
intramuscular injection of a combination of ketamine and xylazine
to fit prostheses on their calvarium to facilitate subsequent place-
ment within a stereotactic frame. On the day of the experiment,
rabbits received 1.75 g/kg ethylcarbamate (urethane) subcu-
taneously and then 10 mg/kg pentobarbital iv to induce deep
anaesthesia. The animals were fixed in stereotactic frames and a
3.5 inch (25 G) spinal needle was introduced into the cisterna
magna. Following the withdrawal of 0.2 mL of CSF, pneumococci
(1  105 cfu in 0.2 mL of saline solution) were injected into the
subarachnoid space. After inoculation, the animals were brought
back to the cages for the night. The next day, the rabbits were
fitted again in the frames using the techniques and anaesthesia
described above. A catheter was fixed in the femoral artery for
serum sampling. A spinal needle was fixed again in the subarach-
noid space. Antibiotics were injected intravenously in standard
doses described in the literature7,8 (100 mg/kg ceftriaxone, 20 mg/
kg vancomycin).
EDP-420 initially was administered at a lower dose (10 mg/kg)
to determine the penetration into inflamed meninges in order to esti-
mate a proper dose for the larger efficacy study. A higher dose of
30 mg/kg was selected as the estimated dose for efficacy based on
EDP-420 pharmacokinetics and pharmacodynamics described by
Maglio9 in mice. Vancomycin was given at 0 and 4 h and ceftriax-
one at 0 h according to their pharmacokinetic properties. CSF
(0.2 mL) was sampled at 0, 1, 2, 4, 5, 6 and 8 h after initiation of
therapy. Blood samples were collected at 0.25, 0.5, 1, 2, 3, 4, 4.25,
4.5, 5, 6, 7 and 8 h after initiation of therapy. Each group included
untreated controls which received comparable volumes of saline.
Determination of antibiotic levels and cfu titres
EDP-420 concentration in serum and CSF was determined by LC/
MS/MS (performed by Enanta Pharmaceuticals, Inc.). cfu were
measured by serial dilution of CSF, plating on agar plates with 5%
sheep blood and incubation overnight at 378C in 5% CO2.
Statistical analysis
The Student t-test and one-way analysis of variance (Newman–
Keuls’s multiple comparisons test) were used for parametric data.
Comparison of positive and negative cultures was analysed by the
two-tailed Fisher exact test. A P value of ,0.05 was considered
significant.
Results
The serum and CSF kinetics of EDP-420 in infected rabbits at
10 mg/kg is presented in Figure 1 and Table 1. After an iv injec-
tion to infected rabbits, EDP-420 serum level peaked at
2.59 mg/L at 0.25 h and decreased rapidly to 0.928 mg/L 2 h
after an injection. During the following 6 h, EDP-420 levels
decreased more slowly with levels of 0.453 mg/L at the end of
the treatment period at 8 h. In the corresponding CSF, EDP-420
concentration increased during the first 2 h and then remained
stable until the end of the 8 h treatment period with an average
Cmax of 0.676 mg/L and an average concentration of 0.479 mg/L
at 8 h. The AUC0–8 values in CSF and serum were 2.48 and
6.53 mg.h/L, respectively. The CSF/serum ratios were 0.28+ 27
and 0.38+ 38 for Cmax and AUC0–8, respectively.
When 10 mg/kg was given intravenously to non-infected
rabbits, there was almost no penetration (only 1%) across the
non-inflamed meninges whereas the serum concentration
remained relatively similar to the infected rabbits at the same
dose (Table 1). However, at the same dose in infected animals,
the concentrations were 25% and 35% higher for Cmax and
AUC than in non-infected animals.
An EDP-420 dose of 30 mg/kg given intravenously to
infected rabbits resulted in a proportional increase in the serum
level from 10 to 30 mg/kg (Figure 2). However, the CSF pen-
etration did not increase at this dose with a Cmax of 0.607 mg/L
and an AUC0–8 of 2.75 mg.h/L which are at a similar level to
the 10 mg/kg dose (Figure 3 and Table 2).
As known from a previous study,7 vancomycin, used in stan-
dard doses (20 mg/kg every 4 h, 2 doses) in rabbits, produced
CSF levels between 1.74 and 4.0 mg/L and ceftriaxone (100
mg/kg) led to CSF levels between 3.5 and 5.5 mg/L.8 During the
entire treatment period, EDP-420 CSF levels remained above the
MIC leading to CSF/MIC ratios between 5 and 8.
Figure 1. Serum and CSF concentration of EDP-420 at a dose of 10 mg/kg
in rabbits infected with penicillin-resistant S. pneumoniae WB4. Filled
squares represent serum levels and filled diamonds represent CSF levels.
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The antibacterial efficacy of EDP-420 against the two pneu-
mococcal strains is presented in Table 3. In the untreated con-
trols, the growth of bacteria was negligible, ,1 log10 cfu/mL
over 8 h. Before the initiation of treatment, the bacterial titre
was significantly higher in the EDP-420 group (6.91+ 0.41
EDP-420 versus 5.88+ 0.70 for the standard regimen, P,
0.004). Against the penicillin-resistant strain, EDP-420 was
bactericidal (20.61+ 0.10 Dlog10 cfu/mL.h) with a decrease of
the viable cell count of 4.80 log10 at the end of the treatment
period, managing to sterilize the CSF of 3 out of 10 rabbits. The
standard regimen based on a combination of vancomycin with
ceftriaxone produced a similar antibacterial activity (20.57+
0.13 Dlog10 cfu/mL.h and 24.52+ 1.30 log10 cfu/mL after 8 h).
At the end of the experimental period, the CSF in 5 out of 10
rabbits was sterile in the comparator regimen. Using the
penicillin- and quinolone-resistant strain, the initial titre was
similar in all groups, ranging from 5.41 to 6.20 log10 cfu/mL. In
the untreated controls, the bacterial growth was slightly more
pronounced after 8 h (þ1.36 log10 cfu/mL compared with
þ0.55 log10 cfu/mL for the penicillin-resistant strain). Both
treatment groups produced similar antibacterial activity
(Table 3) and sterilized the CSF of 5 out of 10 rabbits.
In the in vitro time-killing assays, EDP-420 was tested only
against the penicillin-resistant strain. With concentrations 5 and
10 above the MIC, EDP-420 showed bactericidal activity,
reducing the bacterial titre by 4.5 and 5.5 log10 cfu/mL, respect-
ively after 8 h (Figure 4).
Discussion
S. pneumoniae is one of the leading causes of severe infections,
and is responsible for 500 000 cases of pneumonia, 55 000 cases
of bacteraemia and 6000 cases of meningitis each year in the
USA.1 However, the introduction of the protein–polysaccharide
conjugate vaccine in 2000 in the USA led to a significant
decrease of invasive pneumococcal infections, especially in chil-
dren under 2 years of age.10 Since the first report of penicillin-
resistant pneumococcal isolates in Papua New Guinea and
Australia, increasing resistance rates have been reported world-
wide, especially in several countries in Asia.11 In some tissues
Figure 3. CSF concentration of EDP-420 at dosages of 10 and 30 mg/kg in
non-infected and infected rabbits. Filled diamonds represent CSF levels of
10 mg/kg dose in non-infected rabbits, and filled squares and filled triangles
represent CSF levels of 10 and 30 mg/kg doses in infected rabbits,
respectively.
Figure 2. Serum concentration of EDP-420 at dosages of 10 and 30 mg/kg
in non-infected and infected rabbits. Filled diamonds represent serum levels
of 10 mg/kg in non-infected rabbits, and filled squares and filled triangles
represent serum levels of 10 and 30 mg/kg in infected rabbits, respectively.
Table 1. EDP-420 kinetic parameters at 10 mg/kg iv in uninfected rabbits and rabbits infected with penicillin-resistant S. pneumoniae WB4
Uninfected rabbits Infected rabbits
Cmax (mg/L) AUC0–8 (mg.h/L) t1/2 (h) Cmax (mg/L) AUC0–8 (mg.h/L) t1/2 (h)
CSF 0.0276+0.0136 0.0806+ 0.025 NDa 0.677+ 0.617 2.48+2.37 NDa
Serum 2.32+0.905 6.16+ 0.821 5.15+ 2.65 2.59+ 0.533 6.53+1.13 8.48+6.79
CSF/serum ratio 0.014+0.011 0.013+ 0.006 0.28+ 0.27 0.38+0.38
aCannot be determined, concentration still high at 8 h.
Table 2. EDP-420 kinetic parameters at 30 mg/kg iv in rabbits
infected with penicillin- and quinolone-resistant S. pneumoniae
WB4
Cmax (mg/L) AUC0–8 (mg.h/L) t1/2 (h)
CSF 0.607+1.20 2.75+7.17 NDa
Serum 5.08+1.59 18.6+5.45 5.87+2.07
CSF/serum ratio 0.12+0.20 0.16+0.36
aCannot be determined, concentration still high at 8 h.
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where the antibiotic penetration is limited, as is the case in
meningitis, an inadequate treatment might have devastating con-
sequences, underlining the need for new alternative treatments.
Based on the recent PROTEKT surveillance study,11 all 3362
tested pneumococcal strains were susceptible to telithromycin,
the only ketolide available on the market.
EDP-420 is a new 6,11-bridged bicyclic macrolide antibiotic
belonging to the new bicyclolide family. It is highly effective
against resistant respiratory pathogens including erythromycin-
resistant S. pneumoniae as well as MLS-inducible resistant
Staphylococcus aureus and methicillin-susceptible S. aureus.12
As with all macrolides and ketolides, the mechanism of action
of EDP-420 is based on inhibition of protein synthesis by direct
binding to the 50S subunit of bacterial ribosomes and prevention
of translation and ribosome assembly.13 The good tissue pen-
etration and the excellent pharmacokinetic features (i.e. a long
half-life) seem to be promising properties of EDP-420 which
should be explored further as a potential new treatment regimen
for pneumococcal meningitis, especially when caused by resist-
ant strains.
The penetration of EDP-420 into inflamed meninges was
around 38% at 10 mg/kg. However, the penetration into the
meninges seemed saturated at 30 mg/kg (Tables 1 and 2).
Further experiments with different doses may be needed to
determine the real penetration of EDP-420 into inflamed
meninges and its potential for use in humans.
The very low MIC (0.06 mg/L) against penicillin-resistant
pneumococci and the bactericidal activity of EDP-420, demon-
strated in time-killing assays in vitro (Figure 4), are two prere-
quisites qualifying EDP-420 as a new efficacious agent for
pneumococcal infections. In our experimental meningitis model,
EDP-420 at 1 30 mg/kg had similar efficacy to the standard
regimen of a combination of ceftriaxone (1 100 mg/kg) with
vancomycin (2 20 mg/kg) used in this animal model of menin-
gitis. Even against erythromycin-resistant strains with MICs
between 0.003 and 0.006 mg/L based on a recent study,
EDP-420 is expected to be effective.14
In summary, its excellent efficacy in vivo and its good pen-
etration into the CSF warrant further studies of EDP-420 as a
potential candidate for the treatment of CNS pneumococcal
infections, especially against resistant strains. We are aware that
the penicillin-resistant pneumococcal strain used in this study is
not ideal and a macrolide-resistant strain would have been more
appropriate. On the other hand, this penicillin-resistant strain has
been used in multiple studies allowing a precise comparison of
the efficacies of the different regimens.
Further efficacy and pharmacokinetics–pharmacodynamics
studies are needed. To our knowledge, this preliminary study
shows, for the first time, the efficacy of a bicyclolide class anti-
biotic in experimental meningitis.
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